Wednesday, July 8, 2026

pharma · Colorectal Cancer · Esophageal Varices in NASH Cirrhosis · GALT

Galectin Therapeutics

Galectin Therapeutics clinical programs — 12 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US HQ
2000 Founded
36 Employees
Public company Type
GALT · NYSE Ticker
Company details
Status
Public
HQ
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US
Founded
2000
Employees
36
Programs
12
Drugs
5
Patents
20
Intelligence · Clinical Programs

Galectin Therapeutics projects

12 ClinicalTrials.gov programs sponsored by Galectin Therapeutics.

Galectin Therapeutics has 12 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial
  2. belapectin

    GALECTIN THERAPEUTICS INC

    Prevention of Esophageal Varices

    phase 3 small molecule terminated

    1 trial
  3. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Cancer of the Bile Duct

    phase 2 small molecule terminated

    1 trial
  4. GM-CT-01

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    2 trials
  5. GM-CT-01 plus 5-Fluorouracil

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial
  6. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Hypertension, Portal

    phase 2 small molecule completed

    1 trial
  7. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial
  8. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial
  9. 1 mg/kg GR-MD-02

    GALECTIN THERAPEUTICS INC

    Metastatic Melanoma

    phase 1 mab completed

    1 trial
  10. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Non-Alcoholic Steatohepatitis (NASH)

    phase 1 small molecule completed

    1 trial
  11. GR-MD-02

    GALECTIN THERAPEUTICS INC

    Melanoma

    phase 1 small molecule completed

    1 trial
  12. belapectin

    GALECTIN THERAPEUTICS INC

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Galectin Therapeutics have?

12 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.